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Abstract
Metformin or dimethyl biguanide is the oral antidiabetic drug with the most 
extensive experience of prescribing in the clinical practice of type 2 diabetes 
mellitus. In this chapter, we reviewed the indications, contraindications, and 
adverse drug reactions (ADR) of metformin. The most significant adverse drug 
reactions of metformin are lactic acidosis, allergies, hypoglycemia, vitamin B12 
deficiency, altered taste, and gastrointestinal intolerance. Metformin is contra-
indicated in severe chronic diseases (hepatic, renal, and cardiac failure) or acute 
complications of diabetes (ketoacidosis and hyperosmolar state). Metformin 
is considered by all international guidelines the first-line treatment in type 2 
diabetes mellitus (T2DM) together with medical, nutritional therapy. It is one 
of the most prescribed molecules worldwide. Furthermore, metformin can also 
be prescribed for other diseases like polycystic ovary syndrome or prediabetes 
(impaired glucose tolerance/fasting hyperglycemia). Recent studies have shown 
positive results concerning the use of metformin for cardiovascular or neuro-
protective effects; also, several scientific papers are suggesting an antitumor or 
antiaging effect of metformin. Having such an excellent efficiency in practice, 
thus predicting its sustainability on the pharmaceutical market, research is 
directed toward characterizing metformin action on bacteria genera in the gut. 
Modifying the microbiota composition by pre- and probiotics could improve 
metformin action.
Keywords: metformin, indication, adverse reaction, gastric intolerance, lactic 
acidosis, diabetes
1. Introduction
Metformin or dimethyl biguanide has its origin in traditional herbal medicine 
(Galega officinalis or goat’s rue) that is rich in guanidine. Guanidine was proven to 
have the capacity to lower blood glucose and was used as an antidiabetic treatment 
from the 1920s to 1930s. Its administration was interrupted prematurely due to 
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toxicity. The medicine was valued again between the 1940s and 1950s when Jean 
Sterne observed the low blood glucose values of patients that were treated with 
metformin for influenza. Since then, the drug class of biguanides has received much 
consideration, especially buformin and phenformin in the 1970s and metformin 
after the 1990s [1].
The 60-year history of biguanides’ use is filled with victories and defeats, being 
the oral antidiabetic drug with the most extensive experience of prescribing in the 
clinical practice.
We will review in the following pages the indications, contraindications, and 
adverse drug reactions (ADR) of metformin and the single biguanide approved 
globally for use nowadays.
An ADR according to the World Health Organization is “a response to a drug 
which is noxious and unintended, and which occurs at doses normally used in man 
for the prophylaxis, diagnosis, or therapy of a disease, or the modification of physi-
ological function.” A side effect is “an unintended effect occurring at normal dose 
related to the pharmacological properties” [2].
A contraindication represents “something (such as a symptom or condition) that 
makes a particular treatment or procedure inadvisable” [3].
2. Indications
2.1 Type 2 diabetes mellitus (T2DM)
All international guidelines consider metformin and lifestyle intervention as the 
first-line treatment in adults with T2DM in order to improve glycemic control [4]. 
It can be used either as monotherapy or combination therapy with glucagon-like 
peptide-1 receptor agonist (GLP-1 RA), sodium-glucose co-transporter inhibitor 
(SGLT2i), dipeptidyl peptidase-4 inhibitor (DPP4-I), thiazolidinedione (TZD), 
sulfonylurea (SU), and insulin. Metformin therapy should be continued as long as it 
is well tolerated and not contraindicated. All other agents, including insulin, should 
be added to metformin treatment [4].
2.2 Prediabetes
Metformin can be used in order to prevent or delay the onset of T2DM [5]. 
Although other pharmacological agents have been used in clinical trials (acarbose 
[6–8], orlistat [9], and rosiglitazone [10]), it appears that metformin has the most 
reliable evidence base [11–16]. The vast majority of international guidelines recom-
mend metformin use in prediabetes. It can be used together with a combination of 
a lifestyle intervention for patients with prediabetes: impaired glucose tolerance 
(2-h post-load glucose 140–199 mg/dL), fasting hyperglycemia (100–125 mg/dl), 
or A1C 5.7–6.4% [17–23]. Metformin appears to have a more significant advantage 
when used in patients who are <60 years old and have a BMI >35 kg/m2 or women 
with prior gestational diabetes mellitus [16].
2.3 Type 1 diabetes mellitus (T1DM)
Metformin is sometimes used in T1DM to limit insulin dose requirement [24, 25]. 
The American Diabetes Association states that adding metformin leads to the 
reduction in body weight and can improve lipid levels, but not HbA1c [4, 26]. The 
REMOVAL study suggests that metformin might also reduce atherosclerosis progres-
sion, thus suggesting to improve CVD risk management in type 1 diabetes [27, 28].
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2.4 Gestational diabetes mellitus (GDM)
Lifestyle modification is the first-line therapy for GDM. If glycemic targets are not 
achieved, then insulin treatment is required for lowering blood glucose; metformin 
can also be considered if the patient cannot take or declines insulin [29]. Some con-
trolled randomized trials are proving limited efficacy of metformin during pregnancy 
[30, 31]. Metformin therapy is associated with a lower risk of neonatal hypoglycemia 
and less maternal weight gain than insulin in systematic reviews [32–34]; metformin 
may slightly increase the risk of prematurity, and it crosses the placenta [35]. Thus, 
the ADA considers that metformin should not be used as first-line agents [36].
2.5 Polycystic ovary syndrome (PCOS)
PCOS patients suffer from insulin resistance and hyperinsulinemia [37]. 
Metformin has been used for PCOS treatment [38] for treating the metabolic 
abnormalities of PCOS. A recent meta-analysis [39] demonstrated that metformin 
could decrease testosterone and insulin level in women with PCOS.
2.6 Antitumor or antiaging effect of metformin
Several studies showed an increased life-span when using metformin (4–6% 
in different mouse breeds or a mean life-span increased by 14% and maximum 
life-span increased by 1 month of treatment with metformin is started early in life) 
[40, 41]. In the United Kingdom Prospective Diabetes Study (UKPDS), the use 
of metformin decreased the risk of cardiovascular disease, cancer incidence, and 
overall mortality, compared with other antidiabetic drugs [42].
Epidemiological studies reported a positive result of metformin concerning 
ovarian [43, 44], breast, prostate, or colorectal tumors [45–48] enhancing the 
antitumor effect of metformin. Furthermore, studies are demonstrating a reduced 
incidence of several gastroenterological cancers and a reduction in cancer mortality 
when using metformin [49, 50].
2.7 Cardiovascular or neuroprotective effects
UKPDS was the first study that demonstrated the cardiovascular benefit of 
metformin; the risk of all-cause mortality and acute myocardial infarction was 
significantly reduced in overweight patients with T2DM [42]. The 10-year post-
interventional follow-up of the UKPDS survivor cohort revealed that metformin 
treatment had a long-term benefit on cardiovascular risk [51].
The cardiovascular protective effects of metformin could be explained by the 
reduced level of LDL cholesterol [52], the limitation of weight gain, [53] and the 
improvement of oxidative stress, inflammatory response, and the endothelial cell 
function [54].
It has been reported that patients treated with metformin have lower risk of 
dementia than those with other diabetes medications [55]. Metformin has a better 
protective effect on the domain of verbal learning, working memory, and executive 
function than other diabetic treatments [56].
2.8 Antipsychotic-induced weight gain
Results of meta-analyses of RCTs (primarily in patients with schizophrenia and 
schizoaffective disorder) support the use of metformin for weight loss, preventing 
weight gain associated with second-generation antipsychotics in adult patients [57]. 
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Metformin can be recommended as a second-line option after nonpharmacologic strate-
gies for managing weight gain in patients with mood disorders and is recognized as often 
being used as a secondary prevention strategy for antipsychotic-related weight gain [58].
3. Dosage
The dose for glucose-lowering efficacy is usually in the range of 500–2000 mg/
day. There is no standard dosage regimen for the management of hyperglycemia in 
patients with type 2 diabetes. On the other side, clinically significant responses are 
not seen at doses below 1500–2000 mg per day.
The dosage of metformin must be individualized for every patient considering 
effectiveness and tolerance while not exceeding the maximum recommended daily 
doses (2550 mg in adults and 2000 mg in pediatric patients >10 years of age) (Table 1).
Patients that are receiving immediate-release metformin treatment may be switched 
to extended form once daily with the same total daily dose (up to 2000 mg daily).
In the case of renal impairment, the dosage of metformin must be adjusted 
(Table 2).
4. Adverse drug reactions of metformin
4.1 Lactic acidosis (very rare)
Phenformin and buformin were two potent biguanides that were used in the 
1970s for type 2 diabetes treatment. The Swedish Adverse Drug Reaction Committee 
Renal impairment eGFR
<30 30–45 >45
Initiation Contraindicated Not recommended No dose adjustment 
needed
If eGFR falls during 
treatment
Stop Assess the benefit-risk of 
continuing therapy
No dose adjustment 
needed
Table 2. 
Dosage of metformin for renal impairment.
Initial dose Titration dose Maximum dose
Adults Immediate-
release 
metformin
500 mg/daily or 
850 mg/daily
500 mg/weekly or 
850 mg/2 weeks
2550 mg/daily
Extended-release 
metformin
500 mg/daily or 
1000 mg/daily
500 mg/weekly 2000 mg/daily
Geriatric 
use
With caution; to start at the low end of the dosing range,
assess renal function more frequently
Pediatric 
use 
>10 years 
old
Immediate 
release
500 mg/daily 500 mg/weekly 2000 mg/daily
Extended release Not yet established
Table 1. 
Dosage of metformin.
5Metformin Indications, Dosage, Adverse Reactions, and Contraindications
DOI: http://dx.doi.org/10.5772/intechopen.88675
analyzed the reports from 1965 to 1977 that involved biguanides (0.6% of the total). 
The fact that attracted attention was that in 6% of the cases in which the patient died 
(the majority with lactic acidosis), phenformin was administered [59]. After this 
committee report analysis, the class was used with precaution, and metformin was 
favored over phenformin because there was an early study that showed that type 2 
diabetic patients admitted in the hospital had a higher mean lactate level when they 
were treated with other medicine instead of the first-mentioned earlier [59, 60].
A Cochrane meta-analysis that was published in 2006 that analyzed data from 
206 trials and cohort studies did not find any case of lactic acidosis in metformin-
treated patients or the control group. Also, the lactate level was not significantly 
raised in the metformin group, although there was a small difference between 
patients treated with this biguanide and phenformin [61].
A case-control study with 10.652 Danish type 2 diabetic patients showed that 
the lactic acidosis incidence in patients treated with metformin was 391/100.000 
person-years, but the use of the drug itself did not elevate the risk; associated 
diseases had greater importance [62].
4.2 Allergic reactions (infrequent)
Systemic allergic reactions to metformin are infrequent [63, 64]. It can be used 
in patients with asthma that have hypersensitivity, without increasing the risk of 
related outcomes, meaning hospitalizations, asthma-related emergency room visits, 
or exacerbations [65].
Cutaneous allergic reactions have been described scarcely ever, but clinicians 
should be aware of their existence [66].
4.3 Hypoglycemia (very rare)
In monotherapy as a first-line agent, metformin was proven to be safe and 
beneficial in a recent meta-analysis. The hypoglycemic risk was lower than for 
monotherapy with sulfonylurea [67].
Rare cases in elderly patients, with comorbidities and polypharmacy (angio-
tensin-converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs) or 
combined with malnutrition, have been described [68].
4.4 Vitamin B12 deficiency (rare)
The American Diabetes Association Guidelines recommend that potential 
vitamin B12 deficiency should be taken into consideration and screened in type 
2 diabetes patients long-treated with high-dose metformin (more than 2 g/day) 
[59]. A meta-analysis of 29 studies showed that the metformin-treated group had a 
significantly lower level of this vitamin [69]. The implied mechanisms are:
• The drug acts as a competitor for vitamin B12 absorption.
• It affects the intrinsic factor action.
• It generates bacterial overgrowth because it alters bowel movement [70].
4.5 Altered taste (frequent)
Taste disturbance is an adverse effect that can be caused by the accumulation 
and secretion of metformin in saliva. Lee N et al. demonstrated that the salivary 
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glands express the organic cation transporter-3 (OCT3) in high amounts that is 
responsible for metformin carriage and could be involved in the mechanism of this 
side effect. In animal studies, the OCT3(−/−) mice, the uptake of metformin in the 
saliva was downregulated [71].
4.6 Gastrointestinal intolerance (widespread)
Gastrointestinal side effects include diarrhea, nausea, meteorism, and constipa-
tion and affect approximately 20% of the patients [71, 72].
The hydrochloride salt of metformin is usually administered orally and is 
absorbed mostly by the small intestine. The concentration inside the enterocyte can 
reach up to 300 times the level in the circulation and depends on drug transport by 
organic cation transporter 1 (OCT1) [67]. Also, metformin increases glucose use 
in the anaerobic cycle and lactate production inside the enterocyte. Local higher 
production of lactate could be associated with adverse reactions [73].
Scarpello et al. demonstrated that metformin slows the absorption of bile acids, 
consequently leading to osmotic diarrhea [74]. On the contrary, the serum measures 
of lactate, serotonin, or bile acids were similar in normal and intolerant volunteers 
after a 500-mg dose of metformin, making the authors conclude that the intoler-
ance is probably related to local factors within the lumen or enterocyte [73].
Some authors suggested that a reduced function of OCT1 could have an effect 
on the tolerability of metformin in the digestive system. The population with a 
reduced-function OCT1 alleles also had a higher increase of metformin intoler-
ance. If this population was additionally treated with an OCT1 inhibitor, the risk 
increased even more [75]. Thus, patients that are under treatment with other 
medications that interact with OCT1 could have a higher risk for gastrointestinal 
ADR [75].
There are several formulations like the immediate-release (IR) tablets that result 
in high local concentration, extended-release tablets (XR) that have a prolonged 
discharge of the active molecule due to a dual polymer matrix, and delayed-release 
tablets (DR). The XR and the DR forms help in uniformly spreading out molecules 
along the intestinal membrane and prevent intolerance [75].
4.7 Hypothyroidism (controversial)
Metformin acts by activating adenosine monophosphate-activated protein 
kinase (AMPK), an enzyme that also activates thyroid iodine in vitro models. Thus, 
it was assumed that metformin could alter thyroid function [76]. In healthy volun-
teers, only the level of T3 was decreased by metformin administration, but not the 
iodine uptake, TSH, or fT4 [76].
Following this idea, observational studies proved that metformin treatment 
could reduce thyroid-stimulating hormone (TSH) level, but randomized control 
trials performed afterward failed to certify this hypothesis [77].
5. Contraindications
The indications and efficiency of metformin in type 2 diabetes are clearly stated 
in current guidelines [4] and continue to extend to other branches of medicine. For 
example, the UKPDS study revealed that metformin is associated with a lower risk 
of mortality [37], and some researchers tried to use metformin as an antiaging drug. 
Besides its broad indications, metformin remains contraindicated in many condi-
tions associated with hypoxemia because it can lead to lactic acidosis [78].
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5.1 Ketoacidosis
In type 2 diabetes patients with severe hyperglycemia and ketoacidosis or type 
1 diabetes, insulin treatment should be initiated [4]. When the glycemic values are 
balanced, and if the patient does not have other contraindications, metformin treat-
ment can be started in type 2 diabetes [4].
In type 1 diabetes, metformin is solely administered as an adjuvant because it 
can reduce the insulin requirements [25]. A randomized controlled trial found that 
metformin increases the risk for gastrointestinal adverse events in overweight type 1 
diabetes patients, with no benefit for glycemic control, so a clinician should reach a 
decision depending on patient particularities and response [79].
5.2 Cardiac failure
After the warning regarding lactic acidosis, cardiac failure was put on the list 
with contraindications. Afterward, observational studies [80] and systematic 
reviews [81, 82] showed that metformin could be used in stable heart failure. If 
patients develop congestive heart failure or concomitantly have other contraindica-
tions or acute diseases, metformin should be stopped. The studies realized and 
included in the meta-analysis are very heterogeneous, most of them comparing 
different medications, but with no specifications regarding the mean dose of met-
formin or other classes. Overall, the mortality rate was 22% lower in patients with 
heart failure and type 2 diabetes treated with metformin [82].
5.3 Chronic kidney disease (CKD)
Metformin is restricted in patients with eGFR less than 30 ml/min/1.73 m2 
(stage IV CKD), and dose must be adjusted beginning with an eGFR below 45 ml/
min/1.73 m2 (stage IIIb) [4]. In a cohort study of a national registry, metformin 
was associated with a lower rate of mortality and serious adverse events at an eGFR 
between 45 and 60 ml/min/1.73 m2 and had neutral effects on the same variables at 
eGFR between 30 and 45 ml/min/1.73 m2. Although its effect is less evident in stage 
IV chronic kidney disease, the benefit of biguanide treatment outweighs the ADR 
risk in a 4-year follow-up [82, 83].
5.4 Hepatic failure and cirrhosis
Impaired hepatic function is another warning from the FDA [64]. This term 
includes a broad spectrum of liver pathology, and metformin treatment should be 
tailored. In a retrospective study that included patients with cirrhosis, metformin 
had a protective effect for encephalopathy development [84]. Likewise, in another 
retrospective study, biguanide treatment was continued after cirrhosis diagnosis 
and was associated with improved survival [85]. In patients with cirrhosis second-
ary to hepatitis C virus infection, the risk of hepatocellular carcinoma was reduced 
during a 5-year follow-up [86].
5.5 Respiratory insufficiency
Because the risk of lactic acidosis is higher in patients with altered blood gas 
exchange like in chronic obstructive pulmonary disease (COPD), asthma, restrictive 
pulmonary pathologies, the FDA and EMA recommend precaution [63, 64].  
A randomized clinical trial used metformin in a rapidly escalated dose after a COPD 
exacerbation and showed no amelioration in glycemic profile. This could be since 
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mean in-hospital glycemia was assessed and it usually takes 1–2 weeks for metformin 
to reach its maximum hypoglycemic potential; there were no cases of lactic acidosis, 
and mean serum lactate was similar in the intervention and placebo group [87].
6. Special populations
6.1 Children
Metformin is indicated now in children above 10 years [63, 64], although there 
were studies that included obese participants above 7 years without side effects [88].
6.2 Pregnancy
There are limited data that could not identify a drug-associated risk of miscar-
riage or congenital disabilities. Metformin use was not associated with any of these 
maternal or fetal outcomes in post-marketing studies with small sample size or in 
meta-analyses of the randomized clinical trials that included pregnant women. The 
risk of stillbirth, congenital disabilities, and macrosomia can be increased if the 
patients do not have reasonable control under this oral treatment. Thus, the risk is 
falsely attributed to metformin [89].
6.3 Lactation
Metformin is present in the human milk in insignificant concentration. The 
potential adverse effect on the child or milk production has not been described [89].
6.4 Elderly
There is a study which compared pharmacokinetics and pharmacodynamics 
of metformin in the older population (65–85 years) versus young controls. Results 
showed that the glucose-lowering effect was similar in both groups, although the 
maximum concentration and exposure were two times higher in the advanced age 
population. Usually, it is not recommended in patients above 85 years old because 
they have a reduced eGFR [90].
7. Overdosage
A retrospective cohort study performed in the emergency department analyzed 
56 of self-reported metformin overdose from a total of 2872 cases (1.9%). The 
incidence of hyperlactatemia was 56.4%, and that of metformin-associated lactic 
acidosis (MALA) was 17.9%. When the patient is co-ingested with acetaminophen, 
the risk of MALA was higher. No case resulted in death [91].
Treatment in metformin overdose includes supportive care, gastrointestinal 
decontamination (gastric lavage), alkalinization, and even emergency hemodialysis 
in severe cases [92].
8. Future directions: metformin and metagenome
There were some studies on human microbiota, which suggested that metformin 
induces dysbiosis and promotes nutritional imbalances for specific bacterial types 
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in healthy volunteers [93, 94]. Escherichia sp. has a selective advantage over other 
organisms [95].
Twelve bacterial species that were present at baseline predicted the appear-
ance of gastrointestinal adverse events (self-reported) [94]. Characterizing these 
bacteria genera and modifying the microbiota composition by pre- and probiotics 
could improve metformin action. Also, these bacteria could be set as new targets for 
diabetes treatment.
9. Conclusions
Besides its controversial history, metformin remains the most used medicine in 
type 2 diabetes treatment. Progressive dose increases should be encouraged in order 
to prevent gastrointestinal adverse effects. Lactic acidosis is obsolete if the patient 
does not have other severe comorbidities. The indications of metformin currently 
extend to other areas like oncology, endocrinology, and gastroenterology and 
should offer the scientific world more information about its adverse effects.
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